Skip to main content

Table 6 Estimates of ORSCL and ORMH (95% CI), and ORG (2.5–97.5pct): Japanese data on celecoxib-peripheral edema with study period = 168 and 336 days and Exposure Definition I

From: A novel weighting method to remove bias from within-subject exposure dependency in case-crossover studies

Study period

168 days

336 days

Days in 1 period

1 day

14 days

84 days

1 days

14 days

168 days

M

167

11

1

335

23

1

ORSCL

4.19 (3.16–5.55)

3.39 (2.58–4.45)

2.13 (1.54–2.95)

7.16 (5.27–9.74)

5.97 (4.43–8.05)

3.73 (2.42–5.75)

ORMH

2.45 (1.94–3.09)

2.38 (1.87–3.03)

2.13 (1.54–2.95)

2.95 (2.28–3.82)

2.92 (2.24–3.79)

3.73 (2.42–5.75)

ORG

2.45 (1.87–3.25)

2.38 (1.82–3.15)

2.13 (1.57–2.99)

2.95 (2.14–4.09)

2.92 (2.12–4.03)

3.73 (2.49–6.06)

  1. M is the number of control periods
  2. ORSCL: odds ratio by the standard conditional logistic regression; ORMH: odds ratio by the Mantel-Haenszel method; ORG: odds ratio by the Greenland’s method. 95%CI: 95% confidence interval; 2.5–97.5pct: 2.5 to 97.5 percentiles